Hidradenitis Suppurativa: Painful Nodules and Biologic Therapy

Posted By Kieran Beauchamp    On 27 Feb 2026    Comments (9)

Hidradenitis Suppurativa: Painful Nodules and Biologic Therapy

Hidradenitis suppurativa isn’t just a rash. It’s a relentless cycle of painful lumps, draining abscesses, and scarring that can turn everyday movements into agony. If you’ve been dealing with deep, recurring boils in your armpits, groin, or under your breasts, you’re not alone-and you’re not imagining it. This isn’t acne. It’s not an infection you can just wash away. It’s a chronic inflammatory disease that starts when hair follicles get blocked, triggering a firestorm of immune activity that tears through skin and tissue. For years, doctors had little to offer beyond antibiotics and surgery. But now, a new generation of drugs called biologics is changing the game. Hidradenitis suppurativa (HS) affects between 1% and 4% of people worldwide. It hits women three times more often than men, and most people first notice symptoms between ages 20 and 29. The pain is often described as burning, throbbing, or stabbing. These aren’t surface-level bumps. They’re deep, fistula-like tunnels under the skin that leak pus, scar badly, and keep coming back. Many patients avoid social situations, wear loose clothing even in heat, or skip exercise because of the physical and emotional toll. For decades, treatment was a game of trial and error. Antibiotics like clindamycin or doxycycline were tried first. Hormonal therapies, like birth control pills or spironolactone, helped some women. Surgery-cutting out affected areas-was the last resort. But none of these stopped the inflammation at its source. That changed in 2015, when the FDA approved adalimumab (Humira) as the first-ever biologic for HS. It wasn’t a cure, but it was the first treatment that actually targeted the root cause. Biologics are made from living cells, not chemicals. They’re designed to block specific parts of the immune system that go haywire in HS. In HS, proteins like TNF-alpha, IL-17A, and IL-17F act like alarm bells, telling immune cells to attack healthy skin. Biologics silence those alarms. Adalimumab blocks TNF-alpha. Secukinumab (Cosentyx) locks onto IL-17A. And Bimekizumab (BIMZELX), approved in mid-2024, goes a step further by blocking both IL-17A and IL-17F at the same time. The results are striking. In clinical trials, Adalimumab helped 41.8% of patients see at least a 50% reduction in lesions by week 12. That’s more than double the placebo rate. Secukinumab did even better in longer-term studies: 56.4% of patients still had major improvement after one year. And Bimekizumab blew the doors off both-66.9% of patients hit that 50% improvement mark in just 16 weeks. That’s nearly two out of three people seeing their skin clear up significantly. But not all biologics work the same for everyone. Patients with lots of deep tunnels and scarring (Hurley Stage III) often respond better to TNF-alpha blockers like adalimumab. Those with more inflamed, red, pus-filled nodules (Hurley Stage II) tend to do better with IL-17 inhibitors like secukinumab or bimekizumab. This isn’t random. It’s biology. The type of inflammation driving your HS matters. Real-world data backs this up. On patient forums like MyHSteam and Reddit, users report dramatic changes. One woman on Reddit said her abscesses stopped bursting within four weeks of starting secukinumab. Her pain score dropped from 7 out of 10 to 2. Another man on MyHSteam had been in constant discomfort for eight years-after six weeks on adalimumab, he could finally wear a T-shirt without pain. Still, there are downsides. All biologics require injections, usually once a week or every few weeks. Some people get redness or swelling at the injection site. Others develop upper respiratory infections or feel more tired than usual. The biggest barrier? Cost. In the U.S., adalimumab runs about $5,800 a month, secukinumab $6,200, and bimekizumab $6,900. Even with insurance, out-of-pocket costs can hit $1,200 a month. Many patients delay treatment because they can’t afford it. A 2023 survey found that 33% of biologic users stopped because of price. There’s another hidden benefit: biologics may protect your heart. HS isn’t just a skin disease. It’s linked to higher risks of heart disease, diabetes, and obesity. Studies show patients on biologics often see their triglycerides drop by 15% and HDL (good cholesterol) rise by nearly 9% within six months. That’s not just skin healing-it’s your whole body calming down. Doctors now recommend biologics as a first-line treatment for moderate-to-severe HS, especially if antibiotics or hormones have failed. But timing matters. The earlier you start, the better. Once tunnels form and scars set in, even the best biologic can’t undo the damage. That’s why experts urge patients not to wait. If you’ve had recurrent boils for more than six months, get evaluated. To start, you’ll need screening. Doctors check for tuberculosis, hepatitis B and C, and heart conditions before prescribing biologics. You’ll also need regular blood tests to monitor how your body responds. A good sign? If your IHS4 score (a clinical tool measuring lesion count and severity) drops below 10 by week 12, you’re likely to keep improving long-term. The future is coming fast. Three new biologics are in late-stage trials. Guselkumab, which blocks IL-23, showed 58% improvement in early trials. Spesolimab, targeting IL-36, and TAK-279, a TYK2 inhibitor, are also showing promise. One study found combining bimekizumab with minor surgical drainage led to nearly 90% improvement-far higher than either treatment alone. Access remains uneven. In the U.S., 82% of privately insured patients get approved for biologics. Only 45% of Medicaid patients do. That gap isn’t just unfair-it’s dangerous. Delayed treatment means more scarring, more pain, and higher long-term costs. If you’re struggling with HS, know this: you’re not broken. You’re not lazy. You’re not imagining the pain. There’s a real, science-backed treatment now that can give you back your life. You just need to find the right one-and get started before the damage becomes permanent.

What Hurley Stage Are You In?

Doctors use the Hurley staging system to classify HS severity. It helps decide if biologics are right for you.
  • Stage I: Isolated abscesses, no tunnels or scarring. Often managed with antibiotics or lifestyle changes.
  • Stage II: Recurrent abscesses, single or multiple, with some tunnels and scarring. Biologics are strongly recommended if first-line treatments fail.
  • Stage III: Diffuse or broad involvement with multiple interconnected tunnels and abscesses. Biologics are essential, but surgery may still be needed alongside them.

Biologic Therapy: How They Compare

Comparison of FDA-Approved Biologics for Hidradenitis Suppurativa
Drug Target Dosing HiSCR50 at Week 12-16 Monthly Cost (USD) Key Advantage
Adalimumab TNF-alpha 40 mg weekly or every other week 41.8% $5,800 Best for severe scarring (Stage III)
Secukinumab IL-17A 300 mg weekly for 5 weeks, then every 4 weeks 44.5% $6,200 Strong long-term results; better for inflammatory nodules
Bimekizumab IL-17A and IL-17F 320 mg every 4 weeks after loading dose 66.9% $6,900 Highest efficacy; fastest response
Three biologic drones emit colored beams to neutralize inflammation on a patient's body.

What to Expect When Starting Biologics

  • Weeks 1-4: You may feel more tired. Some report mild flu-like symptoms. This is your immune system adjusting.
  • Weeks 4-8: Pain and swelling begin to ease. New abscesses become less frequent.
  • Weeks 8-12: This is the critical window. Doctors measure improvement using the IHS4 score. If you’re responding, you’ll see fewer new lesions and less drainage.
  • After 12 weeks: If you’re not seeing improvement, your doctor may switch you to another biologic. Don’t give up-many patients respond better to a second option.
A robotic dermatologist projects a healing timeline from severe HS to clear skin.

What You Can Do Alongside Treatment

Biologics work best when paired with lifestyle changes:
  • Quit smoking: Smokers have worse HS and respond poorly to treatment. Quitting improves outcomes by 40%.
  • Maintain a healthy weight: Even a 5-10% weight loss reduces flare frequency.
  • Avoid tight clothing: Friction triggers flares. Choose breathable, loose fabrics.
  • Use gentle skin care: Avoid harsh soaps. Stick to fragrance-free cleansers.
  • Track your flares: Note triggers-stress, diet, menstrual cycle-and share them with your doctor.

What’s Next?

The HS treatment landscape is shifting fast. By 2030, experts predict 70% of moderate-to-severe patients will be on biologics. That’s up from just 28% today. New drugs are coming. Better access is needed. And personalized medicine is on the horizon-researchers have already identified a 12-gene signature that predicts who will respond to adalimumab with 85% accuracy. This isn’t just about skin. It’s about dignity, mobility, sleep, work, and relationships. You deserve a life where you don’t have to choose between pain and comfort. Biologics are giving that back to thousands. If you’re still waiting, ask your dermatologist: Is it time to try one?
Tags: